Key result
Aegeline significantly reduces cardiac injury biomarkers and attenuates inflammation in rat myocardial infarction models.
Why the study?
The cardioprotective effects of aegeline, an alkaloidal amide with antioxidant and anti-inflammatory properties, had not been fully characterized in experimental myocardial injury.
Does aegeline mitigate isoproterenol-induced myocardial infarction in experimental rats?
Does aegeline mitigate isoproterenol-induced myocardial infarction in experimental rats?
Aegeline attenuates experimental myocardial injury in rats by reducing oxidative stress, inflammation, and apoptosis, supported by in silico binding to cardiac injury markers.
Answers are grounded in this paper and cite their sources.
Aegeline may confer cardioprotection in preclinical MI models; leaves open translation to human efficacy or safety.
Background Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Although considerable advances have been made in its diagnosis and management, the development of safe and effective cardioprotective agents remains an active area of investigation. Natural products continue to attract interest as potential therapeutic candidates because of their diverse pharmacological activities. Aegeline, an alkaloidal amide isolated from Aegle marmelos , has demonstrated antioxidant and anti-inflammatory properties; however, its cardioprotective effects in experimental myocardial injury have not been fully characterized. Objective The aim of this work was to assess the cardioprotective effects of aegeline in an experimental MI model. Methods Isoproterenol (ISO) (85 mg/kg, subcutaneouslySC) was employed to trigger acute MI in experimental rats. Aegeline was administered to the rats at doses of 5 and 10 mg (p.o.) on the 29th and 30th day, respectively, followed by ISO (85 mg/kg) (s.c.) on the same days. Results Aegeline exhibited cardioprotective properties against ISO-induced damage, as evidenced by the amelioration of altered histopathological features, reduction in myocardial damage, and improvements in antioxidant and oxidative stress markers, inflammatory indicators, and signaling pathways, along with inhibition of apoptotic expression. In addition, aegeline did not affect liver or kidney function. Molecular docking using AutoDock Vina v1.2.6 revealed the strong binding affinity of aegeline for CK-MB (PDB ID: 3B6R), with key hydrophobic, hydrogen-bonding, and salt bridge interactions. Additional targets included LDH (7DBJ), cTnT (1J1D), and cTnI (7SC2), though CK-MB exhibited the most favorable interaction profile. Molecular dynamics simulations supported these findings through principal component analysis, dynamic cross-correlation, free energy landscape mapping, and generalized born surface area (MM-GBSA) binding free energy analysis. Conclusion This study demonstrates that aegeline attenuates experimental myocardial injury by reducing oxidative stress, inflammation, and apoptosis. Computational analyses support potential molecular interactions with proteins associated with myocardial injury, while the biochemical and histopathological findings provide primary evidence for its cardioprotective activity.
No takes yet. Share an insight, caveat, or question.
Alzarea et al. (2026) studied Isoproterenol-induced myocardial infarction (n=24). Aegeline vs. Isoproterenol alone (disease control) and normal saline (normal control) was evaluated on Cardiac injury biomarkers (LDH, CK-MB, cTnT, cTnI) (p=<0.0001). Aegeline treatment at 5 and 10 mg/kg significantly reduced cardiac injury biomarkers, including LDH and CK-MB (p<0.0001), and attenuated oxidative stress and inflammation in a rat model of myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: